Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865761 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00865761: Completed Phase 1 study, sponsored by Actavis.
NCT00865761 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00865761, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated under fasting conditions.
Interventions
- DRUG Alprazolam 3 mg Extended Release Tablets, single dose
- DRUG XANAX XR® 3 mg tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
What the finished NCT00865761 record still lists
NCT00865761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Alprazolam 3 mg Extended Release Tablets, single dose is the first listed.
NCT00865761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00865761 about?
NCT00865761 is a clinical study titled "A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated un...
What is the current status of trial NCT00865761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00865761?
The interventions under investigation include: Alprazolam 3 mg Extended Release Tablets, single dose (DRUG), XANAX XR® 3 mg tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00865761?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00865761's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia